long time lurker, ex-PNG expat.
Central Bank would never allow the merger of BSP + KSL. The licenses held by the 2 companies would destroy all competition as they are both competitors in the same markets. Sharetrading + Lending + Banking + FX. Kina has both the Superannuation Member Services as well as the Investment Management. The monopoly just wouldn't work. There are a number of small players in the financial markets that I would hope the Central Bank would want to protect and it will be interesting watching how the banking sector pans out with Credit Corp having selected a Core Banking system provider (with the associated strategy) & possibly TISA still in the mix - not sure why that one hasn't moved as it looked like they were after a banking license.
Kina and ANZ was always a given, WBC was a disappointment however I haven't looked at the WBC metrics to see how much of their loan book has moved across to Kina anyway.
BSP are really hurting now with business and retail suffering through the Core Banking Upgrade that went horribly wrong.
- Forums
- ASX - By Stock
- KSL
- Ann: Results of 2023 AGM
Ann: Results of 2023 AGM, page-20
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KSL (ASX) to my watchlist
(20min delay)
|
|||||
Last
95.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $274.4M |
Open | High | Low | Value | Volume |
95.5¢ | 95.5¢ | 94.5¢ | $346.7K | 365.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 47710 | 94.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
95.5¢ | 54359 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 47710 | 0.940 |
1 | 2206 | 0.935 |
7 | 123226 | 0.930 |
1 | 3222 | 0.925 |
4 | 44076 | 0.920 |
Price($) | Vol. | No. |
---|---|---|
0.955 | 54359 | 2 |
0.960 | 16830 | 3 |
0.970 | 13950 | 3 |
0.980 | 95500 | 6 |
0.985 | 5000 | 1 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
KSL (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online